News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Teva Pharmaceutical Industries Limited reported total revenue of 53.44 billion ILS last year. The Generics, Innovative Medicines and Biopharmaceuticals segment was the top performer, contributing 59.53 billion ILS, although this was a decrease from the previous year. The United States was the largest regional …
Sharemaestro market context Trend signal active 52 weeks +71.0%MarketBeat Week in Review – 02/03 - 02/07 Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its innovative medicines …
Sharemaestro market context Trend signal active 52 weeks +71.0%Earnings Call Insights: Corteva (CTVA) Q2 2026 MANAGEMENT VIEW * "The headline for this quarter is straightforward. We are delivering strong results. We are raising our full year outlook, and we are on track to complete our separation on October 1." (CEO & Director …
Sharemaestro market context Trend signal active 52 weeks +1.2%Corteva Inc. (CTVA) stock dropped over 10% after missing second-quarter revenue and earnings estimates and lowering full-year EBITDA guidance. This decline is attributed to reduced crop protection demand, lower commodity prices impacting farmer spending, and distributor destocking due to high interest rates. Analysts have …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Corteva (NYSE:CTVA) reported strong first half 2026 results. The company raised its full year 2026 outlook based on current business performance. Corteva confirmed it is …
Sharemaestro market context Trend signal active 52 weeks +1.2%Key Points Interested in Corteva, Inc.? Here are five stocks we like better. Corteva raised its 2026 outlook after strong first-half results, now targeting operating EBITDA of $4.1 billion–$4.3 billion and operating EPS of $3.60–$3.80. First-half sales rose 4% to $11.3 billion, while EBITDA …
Sharemaestro market context Trend signal active 52 weeks +1.2%Corteva, an agriculture company formed from DowDuPont, plans to spin off its seeds business, Vylor, in late 2026. This move will transform the remaining Corteva entity into a pure-play crop protection company. Currently, seeds generate approximately 66% of Corteva's profits, with crop protection accounting …
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …
Sharemaestro market context Trend signal active 52 weeks +1.2%Corteva Inc. has announced that the separation of its agricultural products division into independent crop protection and seed businesses will take place on December 1, 2026. This move follows a strategic review initiated in 2025 aimed at unlocking shareholder value. Both new companies will …
Corteva (CTVA) reported mixed Q2 2026 results, beating EPS expectations with $2.30 per share but missing revenue forecasts at $6.38 billion. The company's stock subsequently dropped 10.02% to $80.39. Despite ongoing pricing pressure in crop protection, particularly in Brazil, Corteva raised its full-year 2026 …
Corteva, Inc. published a slide deck in conjunction with their Q2 2026 earnings call, where they reported an EPS of $2.30, beating estimates by $0.07. However, the company's revenue of $6.38 billion, a 1.19% year-over-year decrease, missed expectations by $219.12 million. This article provides …
RBF Capital LLC has reduced its stake in Teva Pharmaceutical Industries Ltd. by 60%, selling 30,000 shares and retaining 20,000 shares worth $602,000. This divestment occurred despite Teva reporting strong Q2 revenue of $4.14 billion, surpassing estimates, and raising its 2026 revenue outlook due …
Corteva, Inc. (CTVA) reported mixed Q2 2026 results, with earnings beating estimates but sales missing. The company saw a 1% decline in revenues year-over-year to $6.38 billion, but operating earnings per share increased 4.5% to $2.30. Despite competitive pricing in Crop Protection, strong Seed …
Empowered Funds LLC increased its stake in Corteva, Inc. (NYSE:CTVA) by 36.3% during the first quarter, now owning 125,758 shares valued at $10.53 million. This comes amidst other institutional investors also adjusting their positions in the company. Corteva recently reported strong second-quarter earnings, beating …
Dimensional Fund Advisors LP increased its stake in Teva Pharmaceutical Industries Ltd. by 2.6%, acquiring an additional 73,410 shares and bringing its total holdings to 2.86 million shares valued at approximately $86.2 million. Institutional investors collectively own 54.05% of Teva, whose recent Q2 revenue …
Amundi has significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by acquiring an additional 528,373 shares, bringing its total holdings to over 2.9 million shares. This move reflects continued institutional investment in Corteva, despite a slight dip in the stock's opening price and a …
Corteva, Inc. (NYSE:CTVA) has received a "Moderate Buy" consensus recommendation from twenty-two brokerages, with an average 12-month price target of $90.19. The company recently reported mixed quarterly results, beating EPS estimates but missing on revenue, and issued fiscal 2026 EPS guidance of $3.60-$3.80. Corteva …
Stevanato Group's Alina® pen injector platform has received marketing authorizations in multiple European countries for liraglutide-based combination products used in diabetes and weight management therapies. This expansion signifies broader commercial adoption of the Alina® 30 and Alina® 50 variants, highlighting Stevanato Group's commitment to …
For the quarter ended June 2026, Corteva, Inc. (CTVA) reported revenue of $6.38 billion, down 1.2% over the same period last year. EPS came in at $2.30, compared to $2.20 in the year-ago quarter. The reported revenue represents a surprise of -3.66% over the …
Sharemaestro market context Trend signal active 52 weeks +1.2%Corteva, Inc. (CTVA) came out with quarterly earnings of $2.3 per share, beating the Zacks Consensus Estimate of $2.24 per share. This compares to earnings of $2.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …
Sharemaestro market context Trend signal active 52 weeks +1.2%Investors recently purchased a high volume of put options on Teva Pharmaceutical Industries (NYSE:TEVA), signaling increased hedging or defensive positioning, though not a clear market direction. This comes amidst mixed quarterly results where revenue beat expectations, leading to raised 2026 revenue guidance, but EPS …
Corteva, Inc. (CTVA) has raised its full-year adjusted profit forecast due to strong demand across key crop markets, specifically citing the acreage shift from corn to soybeans. The company now anticipates full-year earnings per share to be between $3.60 and $3.80, up from an …
Corteva, Inc. reported strong Q2 and H1 2026 results, leading the company to raise its full-year 2026 guidance for non-GAAP Operating EBITDA to $4.1-$4.3 billion and Operating EPS to $3.60-$3.80 per share. The company also confirmed it is on track to complete the planned …
Corteva, Inc. (CTVA) reported a strong second quarter, with a profit of $1.16 billion, or $1.73 per share. Adjusted earnings of $2.30 per share surpassed Wall Street expectations, though revenue of $6.38 billion fell short of forecasts. The agriculture company anticipates full-year earnings between …
Corteva is introducing Enclosa herbicide to U.S. soybean farmers, a new product designed for exceptional weed control with up to four weeks of residual activity. It combines encapsulated acetochlor (Group 15) and cloransulam (Group 2), offering multiple modes of action to manage weeds and …
Seed 1H results reflect continued value capture on latest in-demand germplasm and trait technologies, including licensing growth Crop Protection 1H demand for new products and focus on operational excellence helped offset competitive pricing dynamics Full-year 2026 guidance3 increased to reflect strong first half performance, …
Sharemaestro market context Trend signal active 52 weeks +1.2%Corteva Inc. is set to announce its second-quarter earnings, with analysts anticipating a strong performance driven by the peak planting season. The company is also progressing with its plan to separate into two publicly-traded entities by the end of 2026, making this earnings report …
Teva Pharmaceutical Industries reported mixed second-quarter 2026 results, with adjusted earnings missing estimates but revenues slightly beating them. The company's stock rose 9.6% after it raised its 2026 revenue outlook, primarily driven by strong performance from its branded drugs Austedo, Ajovy, and Uzedy, and …
Sharemaestro market context Trend signal active 52 weeks +82.5% · Next-week setup negative 42.4%Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Teva Pharmaceutical Industries reported record quarterly UZEDY sales, with a significant year over year …
Sharemaestro market context Trend signal active 52 weeks +82.5% · Next-week setup negative 42.4%Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after reporting second quarter 2026 results, combining a reported net loss of US$576 million with …
Sharemaestro market context Trend signal active 52 weeks +82.5% · Next-week setup negative 42.4%Stevanato Group S.p.A. announced that its Alina pen injector platform has received marketing authorizations in Europe for liraglutide-based combination products. The approval covers Alina 30 for diabetes therapies and Alina 50 for weight management. The Alina platform is a variable-dose, disposable pen injector designed …
In the past week, Teva Pharmaceutical Industries reported Q2 2026 results showing largely flat sales of US$4,142 million year-on-year but shifting from net income of US$282 million to a net loss of US$576 million, driven in part by impairment charges and acquisition-related costs. Despite …
Sharemaestro market context Trend signal active 52 weeks +82.5% · Next-week setup negative 42.4%Stevanato Group's Alina® pen injector platform has received marketing authorizations in multiple European countries for liraglutide-based combination products used in diabetes and weight management. The approvals for Alina® 30 and Alina® 50 variants highlight the growing demand for injectable therapies, particularly GLP-1 treatments, and …
Search by ticker symbol or company name and select a result to open its chart.